Tranexamic acid, otherwise known as Lysteda or Cyklokapron in the U.S., is often prescribed for excessive bleeding. “It is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Fibrin is the basic framework for the formation of a blood clot in hemostasis.” In addition to its value for treating trauma patients, it has been used to treat cases of excessive menstrual bleeding, to reduce blood loss during orthopedic surgery, as a mouthwash following dental surgery, as well as in obstetrics, cardiac surgery, hemophilia and hereditary angioedema.
If approved, tranexamic acid could be used immediately following trauma when bleeding typically progresses and causes more and more brain damage by reducing the breakdown of blood clots and decreasing the amount of bleeding into the brain thereby preventing brain damage and even death.
“Although the results are not definitive they provide hope about the potential effectiveness of this simple drug for head injury patients. If such an inexpensive and widely practicable treatment were found to improve patient outcomes after head injury this would have major implications for clinical care” Said Dr Pablo Perel.Hopefully, CRASH-3 trials will unveil conclusive results so that such a simple treatment could be incorporated immediately following traumatic brain injuries to increase survival rates and reduce disability, not to mention avoiding extensive and challenging rehabilitation.
Potential of Simple Injection On Patients With Head Injury
© www.mentalhealthblog.com No comments